Tirzepatide (LY3298176) acts at two receptors, the GIP receptor and the GLP-1 receptor. A 2020 study compared its signaling with several separate measurement methods. This guide shows how to read each measurement on its own before comparing them.
Willard and colleagues used HEK293 cells expressing a defined, low level of the human GIP receptor or GLP-1 receptor. Low receptor density means less signal amplification, so differences between compounds are easier to see. The native ligands GIP(1-42) and GLP-1(7-36) served as references.
Before you quote a result, note three things: which cell or membrane system was used, which reference ligand the comparison refers to, and what was measured. A value from a cAMP assay and a value from an arrestin assay are not the same kind of result, even when both are reported as potency.
In the cAMP assays, Tirzepatide was roughly as potent as GIP at the GIP receptor. At the GLP-1 receptor, its potency was about 20-fold lower than that of GLP-1. Even at this step, the comparison has to be stated per receptor and against the right reference.
Assay conditions matter too. Tirzepatide carries a fatty acid chain that binds albumin. Albumin-free assays described its intrinsic potency, while added human serum albumin shifted the measured potency substantially. The native ligands were not affected. A potency value without information about albumin is therefore hard to compare.
The study also measured cAMP over time with a luminescence biosensor. At the GIP receptor, GIP and Tirzepatide had the same kinetic profile. At the GLP-1 receptor, GLP-1 at high concentrations produced a biphasic response, while Tirzepatide stayed monophasic even at the highest concentrations tested.
Two compounds can therefore reach similar levels in an endpoint assay and still differ in how the signal builds and fades. State whether a figure comes from accumulation at one time point or from a time course.
In cell membranes, the study measured activation of the G protein Gαs. Tirzepatide was a full agonist at the GIP receptor but a partial agonist at the GLP-1 receptor, with about half of the maximal effect. β-arrestin recruitment was measured in a different cell system, CHO-K1, and at the GLP-1 receptor the effect was below ten percent of that of GLP-1.
A low arrestin response does not mean the receptor is inactive: the same compound produced clear cAMP generation. It is the combination, more cAMP relative to arrestin, that the authors call biased signaling. The term applies to the assays being compared, not to a property you can read from a single experiment.
How much receptor leaves the cell surface was not measured through cAMP. The authors used three separate methods: tagged receptors on the cell surface, an antibody-based surface assay and confocal microscopy. At the GIP receptor, GIP and Tirzepatide produced equivalent internalization. At the GLP-1 receptor, Tirzepatide reached at most about 40 percent of the effect of GLP-1.
When several methods point the same way, the conclusion is stronger than a single experiment. The results still apply to the cell systems studied and cannot be transferred directly to living organisms. The study dates from 2020 and does not describe material sold by Invus Labs.
For laboratory research only. Not for human or veterinary use.